Investigational Drug Information for CC-99677
✉ Email this page to a colleague
What is the development status for investigational drug CC-99677?
CC-99677 is an investigational drug.
There have been 7 clinical trials for CC-99677.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 25th 2021.
The most common disease conditions in clinical trials are Spondylitis, Ankylosing, Spondylitis, and [disabled in preview]. The leading clinical trial sponsors are Celgene, Bristol-Myers Squibb, and [disabled in preview].
Summary for CC-99677
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 20 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2021-08-25) |
| Vendors | 12 |
Recent Clinical Trials for CC-99677
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine | Bristol-Myers Squibb | Phase 1 |
| A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants | Bristol-Myers Squibb | Phase 1 |
| A Study of CC-99677 in Participants With Active Ankylosing Spondylitis | Celgene | Phase 2 |
Clinical Trial Summary for CC-99677
Top disease conditions for CC-99677
Top clinical trial sponsors for CC-99677
US Patents for CC-99677
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
